Aurora Cannabis Inc ACB Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$5.24 up $0.05, 0.96% at close Nov 6
Last close · Previous close $5.19
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.40Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$5.24up $0.05, 0.96%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$5.19Nov 5
- Volume2.06MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.59MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.56 to $6.36; now $5.24
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ACB beat the S&P 500 in 4 of 7 periods.
| Period | ACB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ACB: up 14.2% S&P 500: down 5.6% | ACB beat the S&P 500 by 19.8 percentage points Beat |
| 3M | ACB: up 75.8% S&P 500: down 4.1% | ACB beat the S&P 500 by 79.9 percentage points Beat |
| YTD | ACB: up 24.2% S&P 500: up 8.7% | ACB beat the S&P 500 by 15.5 percentage points Beat |
| 1Y | ACB: up 20.2% S&P 500: up 10.9% | ACB beat the S&P 500 by 9.3 percentage points Beat |
| Long term | ||
| 3Y | ACB: up 11.0% S&P 500: up 75.0% +3.5% vs +20.5% a year | ACB trailed the S&P 500 by 64.0 percentage points Trailed |
| 5Y | ACB: down 92.1% S&P 500: up 67.8% −39.9% vs +10.9% a year | ACB trailed the S&P 500 by 159.9 percentage points Trailed |
| 10Y | ACB: down 97.0% S&P 500: up 313.1% −29.6% vs +15.2% a year | ACB trailed the S&P 500 by 410.1 percentage points Trailed |
$10,000 invested in ACB 10 years ago (Nov 4, 2016) would be worth about $297 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
ACB beat the S&P 500 in 4 of 7 periods.
| Period | ACB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ACB: up 14.2% S&P 500: down 5.6% | ACB beat the S&P 500 by 19.8 percentage points Beat |
| 3M | ACB: up 75.8% S&P 500: down 4.3% | ACB beat the S&P 500 by 80.1 percentage points Beat |
| YTD | ACB: up 24.2% S&P 500: up 7.8% | ACB beat the S&P 500 by 16.4 percentage points Beat |
| 1Y | ACB: up 20.2% S&P 500: up 9.7% | ACB beat the S&P 500 by 10.5 percentage points Beat |
| Long term | ||
| 3Y | ACB: up 11.0% S&P 500: up 68.8% +3.5% vs +19.1% a year | ACB trailed the S&P 500 by 57.8 percentage points Trailed |
| 5Y | ACB: down 92.1% S&P 500: up 56.9% −39.9% vs +9.4% a year | ACB trailed the S&P 500 by 149.0 percentage points Trailed |
| 10Y | ACB: down 97.0% S&P 500: up 252.6% −29.6% vs +13.4% a year | ACB trailed the S&P 500 by 349.6 percentage points Trailed |
$10,000 invested in ACB 10 years ago (Nov 4, 2016) would be worth about $297 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$1,432.68
Closing high on . Now 99.6% below that record.
Split-adjusted daily closes since Jul 11, 2014.
Stock splits
2
Latest: 1-for-10 on . Share counts adjust after each split.
Both splits
- 1-for-10
- 1-for-12
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY27, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $209.35Mup 4.6%
- Net income
- −$100.86M
- Diluted EPS
- −$1.40
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY25 (Sep 30, 2024) | $59.65M | −$11.07M | −$0.17 |
| Q3 FY25 (Dec 31, 2024) | $61.25M | $19.15M | $0.36 |
| Q4 FY25 (Mar 31, 2025) | $25.11M | −$9.23M | −$0.24 |
| Q1 FY26 (Jun 30, 2025) | $54.07M | −$21.30M | −$0.20 |
| Q2 FY26 (Sep 30, 2025) | $65.48M | −$40.72M | −$0.66 |
| Q3 FY26 (Dec 31, 2025) | $68.75M | −$6.82M | $0.02 |
| Q4 FY26 (Mar 31, 2026) | $27.55M | −$50.47M | −$0.72 |
| Q1 FY27 (Jun 30, 2026) | $47.57M | −$2.84M | −$0.05 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Jun 30, 2022) | $171.58M | −$1.33B | Paused See the note under the price. |
| FY23 (Mar 31, 2023) | $125.86M | −$148.65M | Paused See the note under the price. |
| FY24 (Mar 31, 2024) | $198.26M | −$56.48M | −$1.12 |
| FY25 (Mar 31, 2025) | $200.63M | $164.58K | $0.03 |
| FY26 (Mar 31, 2026) | $232.31M | −$119.11M | −$1.55 |
Margins
- Gross 49.7%
- Operating −12.1%
- Net −48.2%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$35.90MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$20.17MLast 12 months
- Capital spending$15.73MLast 12 months
- −17.1%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $11.99MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paidNot reportedLast 12 months
Balance sheet
- $113.84MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$15.97MAs of Jun 30, 2026
- Net cash$97.86MAs of Jun 30, 2026
- 5.36As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.04As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −26.6%Last 12 months
Over the last 12 months, Aurora Cannabis lost money: its net loss was 26.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −20.3%Last 12 months
Over the last 12 months, Aurora Cannabis’s net loss was 20.3% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Aurora Cannabis Inc
Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance, and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia, and New Zealand with a portfolio of trusted, leading brands including Aurora®, MedReleaf®, Pedanios®, IndiMed™, San Raf®, and Whistler Medical Marijuana Corporation®. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of Opening the World to Cannabis™.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Alberta, Canada
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ACB news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ACB stock FAQ
What is ACB stock’s price today?
Aurora Cannabis (ACB) traded at $5.24 at the close on , up $0.05 (0.96%) from the previous close of $5.19. Over the past 52 weeks it has traded between $2.56 and $6.36.
If you invested $1,000 in ACB 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ACB on would be worth about $30 at the close on , a total return of −97.0%. The same $1,000 would be worth $79 if invested five years ago and $1,202 if invested one year ago. Past performance doesn’t predict future returns.
What is ACB’s P/E ratio?
ACB’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.40).
How much revenue does Aurora Cannabis make?
Aurora Cannabis reported $209.4 million of revenue over the four quarters to , up 4.6% from the twelve months before. In its latest quarter (Q1 FY27, ended ) revenue was $47.6 million, down 12.0% from a year earlier.
Is Aurora Cannabis profitable?
Not over the four quarters to . Aurora Cannabis reported a net loss of $100.9 million across those four quarters on $209.4 million of revenue.
What are ACB’s earnings per share?
ACB’s diluted earnings per share were −$1.40 over the four quarters to , compared with −$0.25 in the twelve months before. The latest quarter (Q1 FY27) brought −$0.05 per share, against −$0.20 a year earlier (how EPS works).
Does ACB pay a dividend?
Aurora Cannabis hasn’t paid a dividend in the last twelve months.
What is ACB’s 52-week high and low?
Over the past 52 weeks ACB has traded as low as $2.56 and as high as $6.36. At $5.24 at the close on , it is 17.6% below that high and 104.7% above the low.
What is ACB’s all-time high?
ACB’s highest closing price was $1,432.68 on , adjusted for stock splits. At $5.24 at the close on , it is 99.6% below that record.
Has ACB stock ever split?
Yes, twice: 1-for-12 on ; 1-for-10 on .
How has ACB stock performed?
Including dividends and measured to the close on , ACB has returned +24.2% so far this year and +20.2% over the past year, and −92.1% over five years (−39.9% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Aurora Cannabis in?
Aurora Cannabis is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, and is headquartered in Alberta, Canada.
What exchange does ACB trade on?
Aurora Cannabis trades on the Nasdaq under the ticker symbol ACB. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.